Sumary of New CAR T-cell therapy uses shorter linker, leading to more potent therapy for ALL:
- July 20, 2021 4 min read Source/Disclosures Published by: Source: Healio Interview Disclosures: The Novartis-Penn Alliance, CHOP Immunotherapy Frontier Program, Emily Whitehead Foundation, V Foundation and Curing Kids Cancer supported this study.
- Ruella reports research funding from Novartis and is listed as an inventor on multiple patents related to CAR T-cell therapy and CD22-directed CAR T cells.
- Back to Healio CD19-directed chimeric antigen receptor T-cell therapies have produced unprecedented response rates among patients with advanced hematologic malignancies, yet many patients who respond to this therapy experience disease relapse.
- To combat this problem, several ongoing clinical trials are evaluating new CAR constructs that target novel antigens or use a bispecific approach targeting multiple antigens.
- One study set out to evaluate CD22 as a target for CAR T-cell immunotherapy.
- After analyzing results of two pilot studies of CD22-directed CAR T-cell therapy among six children and three adults with acute lymphoblastic leukemia, researchers found response rates were lower than anticipated, especially compared with results of another study by the NCI that had used CD22 as a target antigen.
- Healio: Can you explain your group’s rationale for the novel CAR design used in this study?
- We also observed responses to therapy initially in our clinical trial, but the number of patients who responded and their duration of response were suboptimal compared with other groups of patients using similar CAR constructs.